These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20432857)

  • 1. [Methoxy polyethylene glycol epoetin beta].
    Taéron C
    Rev Infirm; 2010 Apr; (159):47-9. PubMed ID: 20432857
    [No Abstract]   [Full Text] [Related]  

  • 2. [Methoxy polyethylene glycol-epoetin beta (Mircera) in the treatment of a patient with chronic kidney disease presenting late-onset hypersensitivity to other epoetins].
    Dávila Fajardo CL; Peña Ortega M; Cabeza Barrera J; Prados Garrido MD
    Nefrologia; 2010; 30(3):372-3. PubMed ID: 20514110
    [No Abstract]   [Full Text] [Related]  

  • 3. [Erythropoietin beta].
    Taéron C
    Rev Infirm; 2006; (122):41-2. PubMed ID: 16881460
    [No Abstract]   [Full Text] [Related]  

  • 4. Methoxy polyethylene glycol-epoetin beta: new drug. Pegylated epoetin beta: risk of cardiovascular disorders.
    Prescrire Int; 2008 Oct; 17(97):191. PubMed ID: 19534043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Darbepoetin alfa.
    Vance R
    Clin J Oncol Nurs; 2003; 7(5):599-600. PubMed ID: 14603561
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methoxy polyethylene glycol-epoetin beta: worth waiting for or a novelty worn off?
    Schmidt RJ
    Expert Opin Pharmacother; 2009 Jun; 10(9):1509-14. PubMed ID: 19505218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CERA: third-generation erythropoiesis-stimulating agent.
    Topf JM
    Expert Opin Pharmacother; 2008 Apr; 9(5):839-49. PubMed ID: 18345959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methoxy polyethylene glycol-epoetin beta (CERA) induced restless legs syndrome.
    Inal S; Gölbaş C; Oneç K; Okyay GU; Derici UB
    Ther Apher Dial; 2012 Aug; 16(4):378-9. PubMed ID: 22817128
    [No Abstract]   [Full Text] [Related]  

  • 10. Route of administration for erythropoiesis-stimulating agents: patient and nursing considerations.
    Holloway M
    Nephrol Nurs J; 2007; 34(5):527-31. PubMed ID: 18041455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
    Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
    Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin for anemia.
    Med Lett Drugs Ther; 1989 Sep; 31(801):85-6. PubMed ID: 2671624
    [No Abstract]   [Full Text] [Related]  

  • 13. Anemia management protocols: providing consistent hemoglobin outcomes.
    Michael M
    Nephrol Nurs J; 2005; 32(4):423-6. PubMed ID: 16180783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward confirmation of the safety and efficacy of methoxy polyethylene glycol-epoetin beta in anemia treatment in patients on hemodialysis: a Macedonian experience.
    Kacarska-Fotevska I; Volckova N; Ilievska K; Donev D
    Croat Med J; 2019 Oct; 60(5):475-478. PubMed ID: 31686463
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of anemia in chronic kidney disease (predialysis) patients: nephrology nursing implications.
    Wish JB; Weigel KA
    Nephrol Nurs J; 2001 Jun; 28(3):341-5. PubMed ID: 12143456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure.
    Schmid H
    Expert Rev Hematol; 2016 Jan; 9(1):5-20. PubMed ID: 26573694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-weekly epoetin-beta in renal anemia: the clinical evidence.
    Albertazzi A
    Contrib Nephrol; 2002; (137):408-11. PubMed ID: 12101986
    [No Abstract]   [Full Text] [Related]  

  • 19. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical administration of epoetin alfa recombinant.
    Taylor BA; Weinstein SM
    J Intraven Nurs; 1992; 15(2):78-82. PubMed ID: 1564606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.